'Great Optimism' Over Complete Responses in dMMR Rectal Cancer

A small trial shows that patients with locally advanced rectal cancer and deficient mismatch repair tumors respond remarkably well to neoadjuvant PD-1 blockade with dostarlimab.
Medscape Medical News

source https://www.medscape.com/viewarticle/975062?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?